Andere talen Immutep Limited

Aandelen

IMM

AU000000IMM6

Beurs gesloten - Australian S.E. Andere beurzen 08:10:52 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,45 ^AUD	+16,88%		+28,57%	+30,43%

24/04	Immutep toont positieve gegevens in onderzoek naar behandeling van plaveiselcelkanker in hoofd en nek	MT
18/04	Immutep Limited stelt vooraanstaand onderzoeksinstituut aan om de eerste klinische studie van IMP761 bij mensen uit te voeren	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	24/04
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761	18/04
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761	18/04
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	18/04
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial	18/04
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76	18/04
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	17/04
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	17/04
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay	17/04
Immutep Obtains Support from Spanish Health Agency for Efti Registrational Trial	17/04
Immutep : Corporate Presentation	26/03
Encouraging results for Immutep's cancer therapies	25/03
Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)	06/03
Wilsons - Dose it higher? Now an option; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	05/03
Immutep Announces First Clinical Data from 90mg Dosing of Efti	05/03
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti	05/03
Immutep Posts 59% Rise in H1 FY24 Revenue, Narrows Net Loss	28/02
Immutep Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27/02
Immutep Quarterly Activities Report Q2 FY24	30/01
Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer	04/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Immutep Limited

Aandelen

IMM

AU000000IMM6

Andere talen

Filters